Actively Recruiting
Evaluate the Efficacy and Safety of Radiotherapy Combined With Ripretinib in the Treatment of Unresectable Advanced GIST
Led by First Affiliated Hospital of Chongqing Medical University · Updated on 2024-07-18
32
Participants Needed
1
Research Sites
161 weeks
Total Duration
On this page
Sponsors
F
First Affiliated Hospital of Chongqing Medical University
Lead Sponsor
P
Peking University Cancer Hospital & Institute
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this prospective study is to learn whether there is a synergistic effect when radiotherapy is combined with ripretinib in the treatment of patients with unresectable advanced GIST. It will also learn about the safety of this regimen.The main questions it aim to answer is: Dose radiotherapy combined with ripretinib prolong the time to disease progression for patients with advanced GIST?
CONDITIONS
Official Title
Evaluate the Efficacy and Safety of Radiotherapy Combined With Ripretinib in the Treatment of Unresectable Advanced GIST
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Voluntary participation and signed informed consent
- Age between 18 and 75 years, male or female
- Histologically confirmed gastrointestinal stromal tumors (GIST)
- Imaging shows unresectable recurrent, metastatic, or locally advanced disease
- ECOG Performance Score of 0 to 2
- Disease progression or documented intolerance after first-, second-, and third-line treatments
- At least one measurable lesion in the abdominal or pelvic cavity that has progressed after frontline treatment
- Adequate organ function and bone marrow reserve
You will not qualify if you...
- Estimated life expectancy less than 3 months
- Previous radiotherapy to the proposed treatment site, or tumor with significant mobility or poor tolerance of radiotherapy in nearby organs
- Deemed unsuitable for radiotherapy after multidisciplinary team discussion
- Any other serious medical conditions that may affect study compliance, safety, or result interpretation
- Female patients who are pregnant, breastfeeding, or plan to become pregnant during the study treatment period
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China, 400016
Actively Recruiting
Research Team
J
Jun Zhang, MD
CONTACT
L
Longhao Li, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here